Skip to main content

Psychotic Disorders

0
Pipeline Programs
11
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 8 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Integrated Biosciences
Integrated BiosciencesCA - San Carlos
2 programs
PASIM programN/A1 trial
Peer-facilitated, Recovery-based Self-illness-management programmeN/A1 trial
Active Trials
NCT07129369Not Yet Recruiting186Est. Oct 2028
NCT06487195Active Not Recruiting198Est. Aug 2027
Bristol Myers Squibb
1 program
AripiprazoleN/ASmall Molecule1 trial
Active Trials
NCT01739127Completed83Est. Feb 2016
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Family Focused Therapy for Clinical High Risk YouthN/A1 trial
Active Trials
NCT04338152Active Not Recruiting220Est. Dec 2026
Verona Pharma
Verona PharmaUK - London
1 program
Health Promotion InterventionN/A1 trial
Active Trials
NCT02807688Completed325Est. Mar 2014
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
Peer-Delivered Decision Support InterventionN/A1 trial
Active Trials
NCT04532034Completed12Est. Mar 2023
Alliance Pharmaceuticals
1 program
Risperdal Long Acting Injectable Antipsychotic MedicationN/A1 trial
Active Trials
NCT00287027Terminated60Est. Dec 2006
Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
SleepioN/A1 trial
Active Trials
NCT04180709Completed45Est. Jul 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
BI 409306PHASE_21 trial
Active Trials
NCT03230097Terminated50Est. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Boehringer IngelheimBI 409306
Integrated BiosciencesPASIM program
Integrated BiosciencesPeer-facilitated, Recovery-based Self-illness-management programme
Angeles TherapeuticsFamily Focused Therapy for Clinical High Risk Youth
Cognition TherapeuticsSleepio
Temple TherapeuticsPeer-Delivered Decision Support Intervention
Bristol Myers SquibbAripiprazole
Verona PharmaHealth Promotion Intervention
Alliance PharmaceuticalsRisperdal Long Acting Injectable Antipsychotic Medication

Clinical Trials (9)

Total enrollment: 1,179 patients across 9 trials

NCT03230097Boehringer IngelheimBI 409306

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Start: Sep 2017Est. completion: Apr 202150 patients
Phase 2Terminated
NCT07129369Integrated BiosciencesPASIM program

Effects of a Peer-facilitated, Acceptance-based Self-learning for Illness Management (PASIM) Program

Start: Jan 2026Est. completion: Oct 2028186 patients
N/ANot Yet Recruiting
NCT06487195Integrated BiosciencesPeer-facilitated, Recovery-based Self-illness-management programme

Effects of a Peer-facilitated, Recovery-focused Self-illness Management Program for First-episode Psychosis

Start: Feb 2023Est. completion: Aug 2027198 patients
N/AActive Not Recruiting
NCT04338152Angeles TherapeuticsFamily Focused Therapy for Clinical High Risk Youth

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

Start: Jan 2021Est. completion: Dec 2026220 patients
N/AActive Not Recruiting
NCT04180709Cognition TherapeuticsSleepio

CBT to Reduce Insomnia and Improve Social Recovery in Early Psychosis

Start: Oct 2020Est. completion: Jul 202345 patients
N/ACompleted
NCT04532034Temple TherapeuticsPeer-Delivered Decision Support Intervention

Facilitating Engagement in Evidence-Based Treatment for Early Psychosis

Start: Sep 2020Est. completion: Mar 202312 patients
N/ACompleted
NCT01739127Bristol Myers SquibbAripiprazole

Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

Start: Nov 2012Est. completion: Feb 201683 patients
N/ACompleted
NCT02807688Verona PharmaHealth Promotion Intervention

Physical Co-morbidity, Poor Health Behaviour and Health Promotion in Verona Patients With Functional Psychoses

Start: Mar 2012Est. completion: Mar 2014325 patients
N/ACompleted
NCT00287027Alliance PharmaceuticalsRisperdal Long Acting Injectable Antipsychotic Medication

Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication

Start: Feb 2006Est. completion: Dec 200660 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.